J. Tobert
Surgery · 2003–2019
A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Surgery — 48 citations into it; #417 of 1,106 by trust here, #536 by citations
- Cancer Research — 13 citations into it
Whom J. Tobert trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts J. Tobert overall
Papers from J. Tobert's perspective
Ordered by how strongly the researchers J. Tobert trusts endorse each paper. Same corpus, a different order for every researcher.
- HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials (The Lancet)
- The safety of statins in clinical practice. (The Lancet)
- Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Primary Prevention (The Lancet)
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. (The Lancet)
- Interpretation of the evidence for the efficacy and safety of statin therapy. (The Lancet)
- Genetic variants associated with Lp(a) lipoprotein level and coronary disease. (New England Journal of Medicine)
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (International Journal of Behavioral Medicine)
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- Cerivastatin and reports of fatal rhabdomyolysis. (New England Journal of Medicine)
- Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study (Circulation)
Their papers
- Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors (2003) — 838 citations
- Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019) — 602 citations
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013) — 661 citations